{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:48:59Z","timestamp":1792244939618,"version":"4.4.0"},"reference-count":107,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Clinically nonfunctioning pituitary tumors (CNFPTs) typically do not cause hormonal excess, progress insidiously, and are often large and invasive at presentation. Complete resection is frequently not attainable; radiotherapy (RT) may effectively limit growth but carries a significant risk of hypopituitarism. Medical therapy with dopamine D2 receptor agonists and\/or somatostatin analogs has been explored in CNFPTs but have yielded inconsistent results, and there is an unmet need for novel efficacious and safe medical therapies. The authors used the PubMed database to identify and review articles published from January 1982 to July 2024, that discussed the medical treatment of CNFPTs. The most commonly studied medical therapies were somatostatin receptor ligands (SRLs) and dopamine D2 receptor agonists. Of 111 patients with CNFPTs treated with SRLs, 31 (28%) exhibited tumor shrinkage. Following dopamine agonist treatment in 355 patients, tumor shrinkage occurred in 113 (32%), tumor stabilization in 182 (51%), and tumor growth in 60 (17%). The efficacy of other less commonly employed therapies such as GnRH analogs, PRRT, and temozolomide was also reviewed. Efficacious and safe medical therapies evaluated in robust randomized placebo-controlled clinical trials are needed to improve the management of CNFPTs.<\/jats:p>","DOI":"10.3390\/ijms26125898","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T08:43:58Z","timestamp":1750322638000},"page":"5898","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Bridge Too Far? Towards Medical Therapy for Clinically Nonfunctioning Pituitary Tumors"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9501-8806","authenticated-orcid":false,"given":"Nikita","family":"Mogar","sequence":"first","affiliation":[{"name":"UCLA Department of Medicine, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0751-7809","authenticated-orcid":false,"given":"Dongyun","family":"Zhang","sequence":"additional","affiliation":[{"name":"UCLA Department of Medicine, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony P.","family":"Heaney","sequence":"additional","affiliation":[{"name":"UCLA Department of Medicine, Los Angeles, CA 90095, USA"},{"name":"UCLA Department of Neurosurgery, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11102-018-0869-3","article-title":"Epidemiology, clinical presentation and diagnosis of non-functioning pituitary adenomas","volume":"21","author":"Ntali","year":"2018","journal-title":"Pituitary"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jama.2016.19699","article-title":"Diagnosis and Treatment of Pituitary Adenomas: A Review","volume":"317","author":"Molitch","year":"2017","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11060-010-0302-x","article-title":"A prospective study of nonfunctioning pituitary adenomas: Presentation, management, and clinical outcome","volume":"102","author":"Chen","year":"2011","journal-title":"J. Neuro-Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1530\/eje.1.02298","article-title":"Non-functioning pituitary adenoma database: A useful resource to improve the clinical management of pituitary tumors","volume":"155","author":"Ferrante","year":"2006","journal-title":"Eur. J. Endocrinol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11102-011-0370-8","article-title":"Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: Results from a case-control study","volume":"15","author":"Fusco","year":"2012","journal-title":"Pituitary"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1530\/EJE-16-0206","article-title":"Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists","volume":"175","author":"Greenman","year":"2016","journal-title":"Eur. J. Endocrinol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3174\/ajnr.A7462","article-title":"The 2021 World Health Organization Classification of Tumors of the Central Nervous System: What Neuroradiologists Need to Know","volume":"43","author":"Osborn","year":"2022","journal-title":"Am. J. Neuroradiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: A summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"key":"ref_9","unstructured":"Larkin, S., and Ansorge, O. (2017). Pathology and pathogenesis of pituitary adenomas and other sellar lesions. Endotext, MDText.com, Inc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/s41379-018-0016-8","article-title":"Epidemiology and biomarker profile of pituitary adenohypophysial tumors","volume":"31","author":"Mete","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/BF03351043","article-title":"Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo","volume":"24","author":"Nielsen","year":"2001","journal-title":"J. Endocrinol. Investig."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1530\/EJE-21-1183","article-title":"Single-cell RNA sequencing in silent corticotroph tumors confirms impaired POMC processing and provides new insights into their invasive behavior","volume":"187","author":"Zhang","year":"2022","journal-title":"Eur. J. Endocrinol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s11102-017-0858-y","article-title":"Silent somatotroph pituitary adenomas: An update","volume":"21","author":"Langlois","year":"2018","journal-title":"Pituitary"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EJE-16-0738","article-title":"Silent somatotroph tumour revisited from a study of 80 patients with and without acromegaly and a review of the literature","volume":"176","author":"Chinezu","year":"2017","journal-title":"Eur. J. Endocrinol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"IJE29","DOI":"10.2217\/ije-2020-0002","article-title":"Somatotroph adenomas: Histological subtypes and predicted response to treatment","volume":"7","author":"Bano","year":"2020","journal-title":"Int. J. Endocr. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.4158\/EP15841.CR","article-title":"Variable Thyroid-Stimulating Hormone Dynamics in \u2018Silent\u2019 Thyrotroph Adenomas","volume":"2","author":"Glynn","year":"2016","journal-title":"AACE Clin. Case Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11102-017-0855-1","article-title":"Histopathological classification of non-functioning pituitary neuroendocrine tumors","volume":"21","year":"2018","journal-title":"Pituitary"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"693","DOI":"10.4103\/1119-3077.158983","article-title":"A thyrotropin-secreting macroadenoma with positive growth hormone and prolactin immunostaining: A case report and literature review","volume":"18","author":"Kuzu","year":"2015","journal-title":"Niger. J. Clin. Pract."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1210\/jc.2018-00688","article-title":"Clinical and Pathological Aspects of Silent Pituitary Adenomas","volume":"104","author":"Drummond","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","article-title":"Overview of the 2022 WHO Classification of Pituitary Tumors","volume":"33","author":"Asa","year":"2022","journal-title":"Endocr. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00401-017-1769-8","article-title":"The 2017 World Health Organization classification of tumors of the pituitary gland: A summary","volume":"134","author":"Lopes","year":"2017","journal-title":"Acta Neuropathol."},{"key":"ref_22","unstructured":"Feingold, K.R., Anawalt, B., Blackman, M.R., Boyce, A., Chrousos, G., Corpas, E., de Herder, W.W., Dhatariya, K., Dungan, K., and Hofland, J. (2000). Non-Functioning Pituitary Adenomas. Endotext, MDText.com, Inc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s11102-017-0856-0","article-title":"Management of nonfunctioning pituitary adenomas (NFAs): Observation","volume":"21","author":"Huang","year":"2018","journal-title":"Pituitary"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1365-2265.2010.03875.x","article-title":"Outcomes of surgical treatment for nonfunctioning pituitary adenomas: A systematic review and meta-analysis","volume":"73","author":"Murad","year":"2010","journal-title":"Clin. Endocrinol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1530\/EJE-11-0566","article-title":"Can we ever stop imaging in surgically treated and radiotherapy-naive patients with non-functioning pituitary adenoma?","volume":"165","author":"Reddy","year":"2011","journal-title":"Eur. J. Endocrinol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s12020-016-0940-7","article-title":"Non-functioning pituitary adenomas: Growth and aggressiveness","volume":"53","author":"Evang","year":"2016","journal-title":"Endocrine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.rpor.2014.09.004","article-title":"Stereotactic radiotherapy and radiosurgery for non-functioning and secreting pituitary adenomas","volume":"21","author":"Minniti","year":"2016","journal-title":"Rep. Pr. Pract. Oncol. Radiother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1210\/jc.2008-0643","article-title":"Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas","volume":"93","author":"Dekkers","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"E533","DOI":"10.1227\/NEU.0000000000001389","article-title":"Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Primary Management of Patients with Nonfunctioning Pituitary Adenomas","volume":"79","author":"Lucas","year":"2016","journal-title":"Neurosurgery"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1677\/ERC-06-0026","article-title":"Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion","volume":"14","author":"Zatelli","year":"2007","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_31","first-page":"1318","article-title":"Chronic somatostatin analog administration in patients with alpha-subunit-secreting pituitary tumors","volume":"75","author":"Katznelson","year":"1992","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1530\/eje.1.02313","article-title":"Quantitative analysis of somatostatin receptor subtype (SSTR1\u20135) gene expression levels in somatotropinomas and non-functioning pituitary adenomas","volume":"156","author":"Taboada","year":"2007","journal-title":"Eur. J. Endocrinol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"369","DOI":"10.33549\/physiolres.932821","article-title":"Dopamine 2 and somatostatin 1-5 receptors coexpression in clinically non-functioning pituitary adenomas","volume":"64","author":"Gabalec","year":"2015","journal-title":"Physiol. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1210\/jc.2008-1826","article-title":"Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly","volume":"94","author":"Neto","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1507\/endocrj.K08E-186","article-title":"Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas","volume":"56","author":"Tateno","year":"2009","journal-title":"Endocr. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1677\/ERC-08-0181","article-title":"Medical therapy for clinically non-functioning pituitary adenomas","volume":"15","author":"Colao","year":"2008","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1210\/edrv-6-4-552","article-title":"Gonadotroph cell adenomas of the pituitary","volume":"6","author":"Snyder","year":"1985","journal-title":"Endocr. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1210\/jc.2004-1093","article-title":"Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly","volume":"90","author":"Bevan","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/BF03348901","article-title":"Octreotide treatment does not affect the size of most non-functioning pituitary adenomas","volume":"16","author":"Gasperi","year":"1993","journal-title":"J. Endocrinol. Investig."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000183785","article-title":"Effects of a chronic treatment with octreotide in patients with functionless pituitary adenomas","volume":"40","author":"Merola","year":"1993","journal-title":"Horm. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/BF03343538","article-title":"The pituitary uptake of 111In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas","volume":"22","author":"Colao","year":"1999","journal-title":"J. Endocrinol. Investig."},{"key":"ref_42","first-page":"1416","article-title":"Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: Effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy","volume":"79","author":"Reichel","year":"1994","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/00006123-199710000-00005","article-title":"A prospective multicenter trial of octreotide in 24 patients with visual defects caused by nonfunctioning and gonadotropin-secreting pituitary adenomas. French Multicenter Octreotide Study Group","volume":"41","author":"Warnet","year":"1997","journal-title":"Neurosurgery"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e038250","DOI":"10.1136\/bmjopen-2020-038250","article-title":"The GALANT trial: Study protocol of a randomised placebo-controlled trial in patients with a 68Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma on the effect of lan reotide on tumour size","volume":"10","author":"Boertien","year":"2020","journal-title":"BMJ Open"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"100923","DOI":"10.1016\/j.lanepe.2024.100923","article-title":"Lanreotide versus placebo for tumour reduction in patients with a 68Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma (GALANT study): A randomised, multicentre, phase 3 trial with blinded outcome assessment","volume":"42","author":"Boertien","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Gulde, S., Wiedemann, T., Schillmaier, M., Valen\u00e7a, I., Lupp, A., Steiger, K., Yen, H.Y., B\u00e4uerle, S., Notni, J., and Luque, R. (2021). Gender-Specific Efficacy Revealed by Head-to-Head Comparison of Pasireotide and Octreotide in a Representative In Vivo Model of Nonfunctioning Pituitary Tumors. Cancers, 13.","DOI":"10.3390\/cancers13123097"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1210\/jcem.82.11.4368","article-title":"Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage","volume":"82","author":"Colao","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/BF03350542","article-title":"Bromocriptine treatment of macroprolactinomas: Studies on the time course of tumor shrinkage and morphology","volume":"5","author":"Nissim","year":"1982","journal-title":"J. Endocrinol. Investig."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1210\/jcem-55-3-589","article-title":"Evidence of dopamine receptors in human growth hormone (GH)-secreting adenomas with concomitant study of dopamine inhibition of GH secretion in a perifusion system","volume":"55","author":"Bression","year":"1982","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1210\/jc.2003-030859","article-title":"Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: Comparison with the effectiveness of cabergoline treatment","volume":"89","author":"Pivonello","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_51","first-page":"377","article-title":"Dopamine Agonists in the Management of Non-Functioning Pituitary Adenomas","volume":"17","author":"Capatina","year":"2021","journal-title":"Acta Endocrinol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Cooper, O., and Greenman, Y. (2018). Dopamine Agonists for Pituitary Adenomas. Front. Endocrinol., 9.","DOI":"10.3389\/fendo.2018.00469"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"281","DOI":"10.7326\/0003-4819-96-3-281","article-title":"Size reduction of extrasellar pituitary tumors during bromocriptine treatment","volume":"96","author":"Wollesen","year":"1982","journal-title":"Ann. Intern. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3171\/jns.1984.60.1.0001","article-title":"Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors","volume":"60","author":"Barrow","year":"1984","journal-title":"J. Neurosurg."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1445-5994.1985.tb04006.x","article-title":"Management of extra-sellar pituitary tumours with bromocriptine: Comparison of prolactin secreting and non-functioning tumours using half-field visual evoked potentials and computerised tomography","volume":"15","author":"Pullan","year":"1985","journal-title":"Aust. N. Z. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF03350660","article-title":"Effect of chronic bromocriptine administration on tumor size in patients with nonsecreting pituitary adenomas","volume":"8","author":"Verde","year":"1985","journal-title":"J. Endocrinol. Investig."},{"key":"ref_57","first-page":"445","article-title":"Bromocriptine therapy as pre-operative adjunct of non-functional pituitary macroadenomas","volume":"108","author":"Loyo","year":"1985","journal-title":"Acta Endocrinol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2265.1989.tb01418.x","article-title":"Bromocriptine therapy for non-functioning pituitary adenoma","volume":"30","author":"Roelfsema","year":"1989","journal-title":"Clin. Endocrinol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1530\/eje.0.1430615","article-title":"Long-term treatment with the dopamine agonist quinagolide of patients with clinically non-functioning pituitary adenoma","volume":"143","author":"Nobels","year":"2000","journal-title":"Eur. J. Endocrinol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1210\/jcem.83.1.4493","article-title":"Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas","volume":"83","author":"Ferone","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1023\/A:1015366923810","article-title":"Minor tumour shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline","volume":"4","author":"Lohmann","year":"2001","journal-title":"Pituitary"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2265.2005.02295.x","article-title":"Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth","volume":"63","author":"Greenman","year":"2005","journal-title":"Clin. Endocrinol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/COC.0000000000000505","article-title":"Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma: A Single-Center, Open-Label, 2-Year Randomized Clinical Trial","volume":"42","author":"Batista","year":"2019","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11102-012-0403-y","article-title":"Short-term treatment with cabergoline can lead to tumor shrinkage in patients with nonfunctioning pituitary adenomas","volume":"16","author":"Garcia","year":"2013","journal-title":"Pituitary"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1046\/j.1365-2265.2000.00951.x","article-title":"Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: Predictive value of pituitary scintigraphy with 123I-methoxybenzamide","volume":"52","author":"Colao","year":"2000","journal-title":"Clin. Endocrinol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/cen.12684","article-title":"Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to cabergoline therapy","volume":"82","author":"Wildemberg","year":"2015","journal-title":"Clin. Endocrinol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11060-022-04149-7","article-title":"Effect of cabergoline on tumor remnant after surgery in nonfunctioning pituitary adenoma","volume":"160","author":"Iglesias","year":"2022","journal-title":"J. Neuro-Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11102-023-01365-w","article-title":"Cabergoline treatment for surgery-na\u00efve non-functioning pituitary macroadenomas","volume":"27","author":"Turjeman","year":"2024","journal-title":"Pituitary"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1365-2265.2001.01172.x","article-title":"In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas","volume":"54","author":"Andersen","year":"2001","journal-title":"Clin. Endocrinol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1210\/jcem-58-2-313","article-title":"The luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6-Pro9-NEt]LHRH increased rather than lowered LH and \u03b1-subunit levels in a patient with an LH-secreting pituitary tumor","volume":"58","author":"Roman","year":"1984","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1365-2265.1984.tb03451.x","article-title":"Discordant serum \u03b1-subunit and FSH concentrations in a woman with a pituitary tumour","volume":"21","author":"Chapman","year":"1984","journal-title":"Clin. Endocrinol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1530\/eje.0.1300339","article-title":"Effects of long-term treatment with the gonadotropin-releasing hormone analog nafarelin in patients with non-functioning pituitary adenomas","volume":"130","author":"Colombo","year":"1994","journal-title":"Eur. J. Endocrinol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1210\/jcem-71-1-92","article-title":"Inhibition of follicle-stimulating hormone secretion from gonadotroph adenomas by repetitive administration of a gonadotropin-releasing hormone antagonist","volume":"71","author":"Daneshdoost","year":"1990","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1210\/jcem-64-3-536","article-title":"Luteinizing hormone-secreting pituitary tumor: Biosynthetic characterization and clinical studies","volume":"64","author":"Klibanski","year":"1987","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1210\/jcem-68-1-81","article-title":"Gonadotropin and alpha-subunit responses to chronic gonadotropin-releasing hormone analog administration in patients with glycoprotein hormone-secreting pituitary tumors","volume":"68","author":"Klibanski","year":"1989","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1210\/jcem-67-1-180","article-title":"Gonadotropin-releasing hormone agonists are unsuccessful in reducing tumoral gonadotropin secretion in two patients with gonadotropin-secreting pituitary adenomas","volume":"67","author":"Sassolas","year":"1988","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/14656566.2020.1845651","article-title":"Perspectives on the current pharmacotherapeutic strategies for management of functional neuroendocrine tumor syndromes","volume":"22","author":"Ito","year":"2021","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s11102-013-0540-y","article-title":"Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma\/carcinoma: Variable clinical response in preliminary evaluation","volume":"17","author":"Maclean","year":"2014","journal-title":"Pituitary"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1530\/EJE-17-0933","article-title":"Treatment of aggressive pituitary tumours and carcinomas: Results of a European Society of Endocrinology (ESE) survey 2016","volume":"178","author":"McCormack","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s11102-016-0745-y","article-title":"How effective is temozolomide for treating pituitary tumours and when should it be used?","volume":"20","author":"Halevy","year":"2017","journal-title":"Pituitary"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1204206","DOI":"10.3389\/fendo.2023.1204206","article-title":"Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain","volume":"14","author":"Lamas","year":"2023","journal-title":"Front. Endocrinol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Lopes-Pinto, M., Lacerda-Nobre, E., Silva, A.L., and Marques, P. (2024). Therapeutical Usefulness of PD-1\/PD-L1 Inhibitors in Aggressive or Metastatic Pituitary Tumours. Cancers, 16.","DOI":"10.3390\/cancers16173033"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"15180","DOI":"10.1073\/pnas.1308827110","article-title":"Structures of human folate receptors reveal biological trafficking states and diversity in folate and antifolate recognition","volume":"110","author":"Wibowo","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.biomaterials.2017.05.034","article-title":"Revisiting the value of competition assays in folate receptor-mediated drug delivery","volume":"138","author":"Jones","year":"2017","journal-title":"Biomaterials"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0083-6729(08)00405-6","article-title":"Structure and function of the reduced folate carrier a paradigm of a major facilitator superfamily mammalian nutrient transporter","volume":"79","author":"Matherly","year":"2008","journal-title":"Vitam. Horm."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Sarmento, B., and das Neves, J. (2018). Chapter 1\u2014From the \u201cmagic bullet\u201d to advanced nanomaterials for active targeting in diagnostics and therapeutics. Biomedical Applications of Functionalized Nanomaterials, Elsevier.","DOI":"10.1016\/B978-0-323-50878-0.00001-X"},{"key":"ref_87","first-page":"4218","article-title":"Differential expression of folate receptor in pituitary adenomas","volume":"63","author":"Evans","year":"2003","journal-title":"Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0083-6729(08)00408-1","article-title":"Folate receptor expression in pituitary adenomas cellular and molecular analysis","volume":"79","author":"Evans","year":"2008","journal-title":"Vitam. Horm."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.2967\/jnumed.108.061689","article-title":"In Vivo Assay of Folate Receptors in Nonfunctional Pituitary Adenomas with 99mTc-Folate SPECT\/CT","volume":"51","author":"Galt","year":"2010","journal-title":"J. Nucl. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1210\/en.2012-2128","article-title":"Antiproliferative, antiinvasive, and proapoptotic activity of folate receptor \u03b1-targeted liposomal doxorubicin in nonfunctional pituitary adenoma cells","volume":"154","author":"Liu","year":"2013","journal-title":"Endocrinology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/17458080.2021.2016711","article-title":"Targeting pituitary adenomas with folate-conjugated multiple drug decorated liposomal formulations for improved antiproliferative anticancer efficacy","volume":"17","author":"Hu","year":"2022","journal-title":"J. Exp. Nanosci."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"437","DOI":"10.7887\/jcns.15.437","article-title":"Molecular Targeting and Imaging of Non-Functional Pituitary Tumors: Preliminary Results","volume":"15","author":"Evans","year":"2006","journal-title":"Jpn. J. Neurosurg."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1210\/en.2013-1182","article-title":"Folate Receptor-Mediated Drug Targeting: A Possible Strategy for Nonfunctioning Pituitary Adenomas?","volume":"154","author":"Lee","year":"2013","journal-title":"Endocrinology"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Cheng, T., Wang, Y., Lu, M., Zhan, X., Zhou, T., Li, B., and Zhan, X. (2019). Quantitative Analysis of Proteome in Non-functional Pituitary Adenomas: Clinical Relevance and Potential Benefits for the Patients. Front. Endocrinol., 10.","DOI":"10.3389\/fendo.2019.00854"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.18632\/aging.202304","article-title":"Genomic and transcriptomic analysis of pituitary adenomas reveals the impacts of copy number variations on gene expression and clinical prognosis among prolactin-secreting subtype","volume":"13","author":"Chen","year":"2020","journal-title":"Aging"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Mangili, F., Esposito, E., Treppiedi, D., Catalano, R., Marra, G., Di Muro, G., Barbieri, A.M., Locatelli, M., Lania, A.G., and Mangone, A. (2022). DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.867822"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1210\/jc.2009-1641","article-title":"Effect of Everolimus on Cell Viability in Nonfunctioning Pituitary Adenomas","volume":"95","author":"Zatelli","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1158\/0008-5472.CAN-09-2951","article-title":"The Somatostatin Analogue Octreotide Confers Sensitivity to Rapamycin Treatment on Pituitary Tumor Cells","volume":"70","author":"Cerovac","year":"2010","journal-title":"Cancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1210\/jc.2018-02461","article-title":"Effect of Everolimus in Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas","volume":"104","author":"Zhang","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s11102-023-01340-5","article-title":"The treatment of aggressive prolactinomas with everolimus","volume":"26","author":"Lin","year":"2023","journal-title":"Pituitary"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11102-011-0341-0","article-title":"New targeted therapies in pituitary carcinoma resistant to temozolomide","volume":"15","author":"Jouanneau","year":"2012","journal-title":"Pituitary"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s12022-019-9568-5","article-title":"An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors","volume":"30","author":"Alshaikh","year":"2019","journal-title":"Endocr. Pathol."},{"key":"ref_103","first-page":"118","article-title":"Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors","volume":"12","author":"Lau","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1210\/jcem.85.3.6485","article-title":"Angiogenesis in Pituitary Adenomas and the Normal Pituitary Gland","volume":"85","author":"Turner","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"989574","DOI":"10.1155\/2014\/989574","article-title":"Correlations of Vascular Architecture and Angiogenesis with Pituitary Adenoma Histotype","volume":"2014","author":"Takano","year":"2014","journal-title":"Int. J. Endocrinol."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Dai, C., Liang, S., Sun, B., Li, Y., and Kang, J. (2021). Anti-VEGF Therapy in Refractory Pituitary Adenomas and Pituitary Carcinomas: A Review. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.773905"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Lamb, L.S., Sim, H.-W., and McCormack, A.I. (2020). Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature\u2014\u201cAre We There Yet?\u201d. Cancers, 12.","DOI":"10.3390\/cancers12020308"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/12\/5898\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:55:05Z","timestamp":1760032505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/12\/5898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":107,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["ijms26125898"],"URL":"https:\/\/doi.org\/10.3390\/ijms26125898","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,19]]}}}